# EVALUATION OF DIFFERENT PROPHYLACTIC INTERVENTIONS TOWARD COVID-19 IN SOLID ORGAN TRANSPLANT PATIENTS

> **NCT05629923** · — · COMPLETED · sponsor: **University of Rome Tor Vergata** · enrollment: 306 (actual)

## Conditions studied

- COVID-19 Pandemic
- Transplant-Related Disorder

## Interventions

- **DRUG:** tixagevimab-cilgavimab(AZD7442, AstraZeneca)

## Key facts

- **NCT ID:** NCT05629923
- **Lead sponsor:** University of Rome Tor Vergata
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-01
- **Primary completion:** 2022-11-01
- **Final completion:** 2022-11-30
- **Target enrollment:** 306 (ACTUAL)
- **Last updated:** 2022-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05629923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05629923, "EVALUATION OF DIFFERENT PROPHYLACTIC INTERVENTIONS TOWARD COVID-19 IN SOLID ORGAN TRANSPLANT PATIENTS". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05629923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*